1887

Abstract

Commonly used human adenovirus (HAdV)-5-based vectors are restricted by their tropism and pre-existing immunity. Here, we characterized novel HAdV-5 vectors pseudotyped with hypervariable regions (HVRs) and surface domains (SDs) of other HAdV types. Hexon-modified HAdV-5 vectors (HV-HVR5, HV-HVR12, HV-SD12 and HV-SD4) could be reconstituted and amplified in human embryonic kidney cells. After infection of various cell lines, we measured transgene expression levels by performing luciferase reporter assays or coagulation factor IX (FIX) ELISA. Dose-dependent studies revealed that luciferase expression levels were comparable for HV-HVR5, HV-SD12 and HV-SD4, whereas HV-HVR12 expression levels were significantly lower. Vector genome copy numbers (VCNs) from genomic DNA and nuclear extracts were then determined by quantitative real-time PCR. Surprisingly, determination of cell- and nuclear fraction-associated VCNs revealed increased VCNs for HV-HVR12 compared with HV-SD12 and HV-HVR5. Increased nuclear fraction-associated HV-HVR12 DNA molecules and decreased transgene expression levels were independent of the cell line used, and we observed the same effect for a hexon-modified high-capacity adenoviral vector encoding canine FIX. In conclusion, studying hexon-modified adenoviruses demonstrated that HVRs but also flanking hexon regions influence uptake and transgene expression of adenoviral vectors.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000328
2016-01-01
2020-04-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/1/160.html?itemId=/content/journal/jgv/10.1099/jgv.0.000328&mimeType=html&fmt=ahah

References

  1. Alba R., Bradshaw A. C., Parker A. L., Bhella D., Waddington S. N., Nicklin S. A., van Rooijen N., Custers J., Goudsmit J., other authors. 2009; Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood114:965–971 [CrossRef][PubMed]
    [Google Scholar]
  2. Amicone L., Spagnoli F. M., Späth G., Giordano S., Tommasini C., Bernardini S., De Luca V., Della Rocca C., Weiss M. C., other authors. 1997; Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J16:495–503 [CrossRef][PubMed]
    [Google Scholar]
  3. Bradshaw A. C., Coughlan L., Miller A. M., Alba R., van Rooijen N., Nicklin S. A., Baker A. H.. 2012; Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J Control Release164:394–402 [CrossRef][PubMed]
    [Google Scholar]
  4. Bruder J. T., Chen P., Semenova E., Thomas C. A., Konovalova S., Ekberg G., Ettyreddy D., McVey D., Gall J. G., other authors. 2013; Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors. J Virol87:9661–9671 [CrossRef][PubMed]
    [Google Scholar]
  5. Cassany A., Ragues J., Guan T., Bégu D., Wodrich H., Kann M., Nemerow G. R., Gerace L.. 2015; Nuclear import of adenovirus DNA involves direct interaction of hexon with an N-terminal domain of the nucleoporin Nup214. J Virol89:1719–1730 [CrossRef][PubMed]
    [Google Scholar]
  6. Coughlan L., Bradshaw A. C., Parker A. L., Robinson H., White K., Custers J., Goudsmit J., Van Roijen N., Barouch D. H., other authors. 2012; Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther20:2268–2281[CrossRef]
    [Google Scholar]
  7. Crawford-Miksza L., Schnurr D. P.. 1996; Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol70:1836–1844[PubMed]
    [Google Scholar]
  8. Doronin K., Flatt J. W., Di Paolo N. C., Khare R., Kalyuzhniy O., Acchione M., Sumida J. P., Ohto U., Shimizu T., other authors. 2012; Coagulation factor X activates innate immunity to human species C adenovirus. Science338:795–798 [CrossRef][PubMed]
    [Google Scholar]
  9. Ebner K., Pinsker W., Lion T.. 2005; Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol79:12635–12642 [CrossRef][PubMed]
    [Google Scholar]
  10. Gahéry-Ségard H., Farace F., Godfrin D., Gaston J., Lengagne R., Tursz T., Boulanger P., Guillet J.-G.. 1998; Immune response to recombinant capsid proteins of adenovirus in humans: antifibre and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol72:2388–2397[PubMed]
    [Google Scholar]
  11. Gall J. G. D., Crystal R. G., Falck-Pedersen E.. 1998; Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol72:10260–10264[PubMed]
    [Google Scholar]
  12. Gallaher S. D., Berk A. J.. 2013; A rapid Q-PCR titration protocol for adenovirus and helper-dependent adenovirus vectors that produces biologically relevant results. J Virol Methods192:28–38 [CrossRef][PubMed]
    [Google Scholar]
  13. Hausl M. A., Zhang W., Muther N., Rauschhuber C., Franck H. G., Merricks E. P., Nichols T. C., Kay M. A., Ehrhardt A.. 2010; Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther18:1896–1906[CrossRef]
    [Google Scholar]
  14. Jager L., Hausl M. A., Rauschhuber C., Wolf N. M., Kay M. A., Ehrhardt A.. 2009; A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc4:547–564 [CrossRef][PubMed]
    [Google Scholar]
  15. Khare R., May S. M., Vetrini F., Weaver E. A., Palmer D., Rosewell A., Grove N., Ng P., Barry M. A.. 2011; Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther19:1254–1262[CrossRef]
    [Google Scholar]
  16. Ma J., Duffy M. R., Deng L., Dakin R. S., Uil T., Custers J., Kelly S. M., McVey J. H., Nicklin S. A., Baker A. H.. 2015; Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo . PLoS Pathog11:e1004673 [CrossRef][PubMed]
    [Google Scholar]
  17. Mück-Häusl M., Solanki M., Zhang W., Ruzsics Z., Ehrhardt A.. 2015; Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses. Nucleic Acids Res43:e50 [CrossRef][PubMed]
    [Google Scholar]
  18. Reddy V. S., Natchiar S. K., Stewart P. L., Nemerow G. R.. 2010; Crystal structure of human adenovirus at 3.5 A resolution. Science329:1071–1075 [CrossRef][PubMed]
    [Google Scholar]
  19. Roberts D. M., Nanda A., Havenga M. J., Abbink P., Lynch D. M., Ewald B. A., Liu J., Thorner A. R., Swanson P. E., other authors. 2006; Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature441:239–243 [CrossRef][PubMed]
    [Google Scholar]
  20. Roy S., Shirley P. S., McClelland A., Kaleko M.. 1998; Circumvention of immunity to the adenovirus major coat protein hexon. J Virol72:6875–6879[PubMed]
    [Google Scholar]
  21. Sprangers M. C., Lakhai W., Koudstaal W., Verhoeven M., Koel B. F., Vogels R., Goudsmit J., Havenga M. J., Kostense S.. 2003; Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol41:5046–5052 [CrossRef][PubMed]
    [Google Scholar]
  22. Sumida S. M., Truitt D. M., Lemckert A. A., Vogels R., Custers J. H., Addo M. M., Lockman S., Peter T., Peyerl F. W., other authors. 2005; Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol174:7179–7185 [CrossRef][PubMed]
    [Google Scholar]
  23. Trotman L. C., Mosberger N., Fornerod M., Stidwill R. P., Greber U. F.. 2001; Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol3:1092–1100 [CrossRef][PubMed]
    [Google Scholar]
  24. Waddington S. N., McVey J. H., Bhella D., Parker A. L., Barker K., Atoda H., Pink R., Buckley S. M., Greig J. A., other authors. 2008; Adenovirus serotype 5 hexon mediates liver gene transfer. Cell132:397–409 [CrossRef][PubMed]
    [Google Scholar]
  25. Youil R., Toner T. J., Su Q., Chen M., Tang A., Bett A. J., Casimiro D.. 2002; Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther13:311–320 [CrossRef][PubMed]
    [Google Scholar]
  26. Zhang W., Muck-Hausl M., Wang J., Sun C., Gebbing M., Miskey C., Ivics Z., Izsvak Z., Ehrhardt A.. 2013; Integration profile and safety of an adenovirus hybrid-vector utilizing hyperactive sleeping beauty transposase for somatic integration. PLoS One8:e75344 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000328
Loading
/content/journal/jgv/10.1099/jgv.0.000328
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error